Evidence map›Paper›PMID 36551710›Full record

ArticleCancers2022

A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [

Dongho Shin, Seunggyun Ha, Joo Hyun O, Seung Ah Rhew, Chang Eil Yoon, Hyeok Jae Kwon, Hyong Woo Moon, Yong Hyun Park, Sonya Youngju Park, Chansoo Park and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dongho ShinDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0001-8496-8825
Seunggyun HaDepartment of Nuclear Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Joo Hyun ODepartment of Nuclear Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0002-6568-5915
Seung Ah RhewDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Chang Eil YoonDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Hyeok Jae KwonDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Hyong Woo MoonDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0002-9352-3411
Yong Hyun ParkDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Sonya Youngju ParkDepartment of Nuclear Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Chansoo ParkResearch Institute of Labeling, FutureChem Co., Ltd., Seoul 04793, Republic of Korea.
Dae Yoon ChiResearch Institute of Labeling, FutureChem Co., Ltd., Seoul 04793, Republic of Korea.ORCID 0000-0002-9862-3286
Ie Ryung YooDepartment of Nuclear Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Ji Youl LeeDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0001-6775-1157

Funding

National Research Foundation of Korea 2018R1D1A1A02086383National Research Foundation of Korea 2022R1A2C1009770National Research Foundation of Korea 2022R1I1A1A01069887
6 · The paper itself

Abstract

[

Indexed as

lutetium-177metastatic castration-resistant prostate cancerPSMAradiopharmaceutical therapy

Identifiers

PMID36551710
PMCPMC9777064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.